Hawthorne W J, Allen R D, Greenberg M L, Grierson J M, Earl M J, Yung T, Chapman J, Ekberg H, Wilson T G
National Pancreas Transplant Unit, Westmead Hospital, NSW, Australia.
Transplantation. 1997 Feb 15;63(3):352-8. doi: 10.1097/00007890-199702150-00004.
The results of simultaneous pancreas and kidney transplantation (SPK) cannot be matched by pancreas transplantation alone (PTA), in part because an independent diagnosis of pancreas graft rejection remains difficult. The relationship between rejection of the pancreas and rejection of the kidney is poorly understood, and it is not known whether simultaneous transplantation of both organs confers true protection to either graft. To study these questions, reliable canine allotransplant models of kidney transplantation alone (KTA), PTA, and SPK were established. Sixty-seven mongrel dogs received KTA (n=21), PTA (n=23), or SPK (n=23) with either no immunosuppression, low-dose cyclosporine (CsA)-based immunosuppression, or high-dose CsA-based immunosuppression. Needle core biopsy (NCB) and fine needle aspiration biopsy (FNAB) were performed at 0, 2, 4, 7, 9, 11, 14, 21, and 30 days or at the time of graft failure. Pancreas and kidney graft survival after SPK was significantly shorter in dogs given low-dose CsA than in dogs given high-dose CsA (pancreas, P<0.04; kidney, P<0.03). Concurrent NCBs and FNABs were performed on 227 occasions in pancreas grafts and 229 occasions in kidney grafts. The time to initial evidence of rejection by NCB was not different in any immunosuppressed group. Synchronous rejection occurred in 73% of immunosuppressed SPK biopsies. Kidney-only rejection occurred in 23% of biopsies and pancreas-only rejection occurred in only 3% after SPK. All markers of pancreas graft rejection were poor, with the most sensitive being NCB of the simultaneously transplanted kidney. In summary, recipients of SPK required more immunosuppression than recipients of PTA, and improved PTA survival should be achievable with more sensitive markers of rejection. Markers of kidney rejection were the most sensitive indicators of pancreas rejection, and independent pancreas rejection was uncommon after SPK.
同时进行胰腺和肾脏移植(SPK)的效果无法仅通过胰腺移植(PTA)来匹配,部分原因是胰腺移植排斥反应的独立诊断仍然困难。胰腺排斥反应与肾脏排斥反应之间的关系尚不清楚,而且两个器官同时移植是否能真正保护任一移植器官也不清楚。为了研究这些问题,建立了可靠的犬类同种异体移植模型,分别为单纯肾脏移植(KTA)、PTA和SPK。67只杂种犬接受了KTA(n = 21)、PTA(n = 23)或SPK(n = 23),分别采用无免疫抑制、低剂量环孢素(CsA)为基础的免疫抑制或高剂量CsA为基础的免疫抑制。在第0、2、4、7、9、11、14、21和30天或移植失败时进行针芯活检(NCB)和细针穿刺活检(FNAB)。接受低剂量CsA的犬进行SPK后,胰腺和肾脏移植的存活时间明显短于接受高剂量CsA的犬(胰腺,P<0.04;肾脏,P<0.03)。对胰腺移植进行了227次同时的NCB和FNAB,对肾脏移植进行了229次。在任何免疫抑制组中,NCB首次出现排斥反应的时间没有差异。73%的免疫抑制SPK活检出现同步排斥反应。SPK后,仅肾脏排斥反应出现在23%的活检中,仅胰腺排斥反应仅出现在3%的活检中。胰腺移植排斥反应的所有指标都很差,最敏感的是同时移植肾脏的NCB。总之,SPK受者比PTA受者需要更多的免疫抑制,通过更敏感的排斥反应指标应该可以提高PTA的存活率。肾脏排斥反应指标是胰腺排斥反应最敏感的指标,SPK后独立的胰腺排斥反应并不常见。